Slides
Page 1
Corporate Presentation January 2026 Medicine is our platform. Accessibility is our cure.
Page 2
This presentation contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including, without limitation, statements concerning: the estimated addressable patient population, market, and revenue opportunity for aleniglipron; any expectations regarding the potential benefits, tolerability and safety profile, accessibility, dose flexibility, scalability, cost, combinability, capability, efficacy, convenience, expected effects, and future application of aleniglipron; the Company’s belief that data to date from the ACCESS, ACCESS II, Body Composition and Open Label Extension studies provide a strong foundation for the Phase 3 clinical development of aleniglipron; the belief that all key questions have been answered by the studies to date; the expected size and design for the Phase 3 trial; any presumption that topline, interim or preliminary data will be representative of final data or data in later clinical trials; the belief that the Company is well positioned to lead with a differentiated and highly scalable pi peline of oral small molecule medicines designed to address the significant unmet needs in obesity and related metabolic diseases; the belief that there is potential for expansion beyond obesity, including chronic kidney disease , metabolic associated steatohepatitis, heart failure, sleep apnea, type 2 diabetes mellitus, osteoarthritis, and addiction; plans to conduct FDA regulatory interactions; the expected timing of topline data readouts fro m the Open Label Extension, ACCESS II Extension, Body Composition, maintenance and T2DM studies; the planned initiation of the ACCG-3535 Phase 1 study and the timing thereof; the expected timing of study results from the Phase 1 ACCG-2671 study; and the Company’s future plans and prospects. In addition, when or if used, the words and phrases “believe,” “may,” “potential,” “to be,” “will,” and similar expressions and their variants, as they relate to the Company may identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Although the Company believes the expectations reflected in such forward-looking statements are reasonable, the Company can give no assurance that such expectations will prove to be correct. Readers are cautioned that actual results, levels of activity, safety, performance or events and circumstances could differ materially from those expressed or implied in the Company’s forward-looking statements due to a variety of risks and uncertainties, which include, without limitation: risks and uncertainties related to topline results that the Company reports is based on preliminary analysis of key efficacy and safety data, and such data may change following a more comprehensive review of the data related to the clinical trial and such topline data may not accurately reflect the complete results of a clinical trial, the preliminary nature of the results due to the length of the study and sample size and results from earlier clinical studies not necessarily being predictive of future results; potential delays in the commencement, enrollment and completion of the Company’s planned clinical studies; the Company’s ability to advance aleniglip ron, ACCG-2671, ACCG-3535, ANPA-0073, LTSE-2578, and its other therapeutic candidates, obtain regulatory approval of, and ultimately commercialize the Company’s therapeutic candidates; competitive pro ducts or approaches limiting the commercial value of the Company’s product candidates; the timing and results of preclinical and clinical studies; the Company’s ability to fund development activities and achieve development goals; the Company's reliance on third parties, including clinical research organizations, manufacturers, suppliers and collaborators, over which it may not always have full control; general geopolitical and macroeco nomic conditions, including as a result of tariffs and various global conflicts; the Company’s ability to protect its intellectual property; and other risks and uncertainties described in the Company’s filings with the Securitie s and Exchange Commission (SEC), including the Company’s latest Quarterly Report on Form 10-Q and future reports the Company may file with the SEC from time to time. All forward-looking statements contained in this presentation speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law. This presentation discusses product candidates that are under clinical study and which have not yet been approved for marketing by the U.S. Food and Drug Administration. No representation is made as to the safety or effectiveness of these product candidates for the use for which such product candidates are being studied. This presentation may incorporate publicly-available third-party data that we have not independently verified. There are risks inherent in conducting cross-trial comparisons and the results should be interpreted with caution. The presentation of such third-party data does not represent a head-to-head comparison of how our product candidates performed against any other third-party product candidate or study. Rather, such third-party data has been pulled by us from publicly-available sources for supplemental informational purposes, only. We caution you that any comparisons against third-party data set forth herein should not be viewed as a side-by-side comparison, and you should not rely on the completeness or accuracy of our presentation of the results of any third -party drug candidate in these slides, due to differences in study design, how other companies quantify or qualify eligibility criteria, and how results are recorded, among other distinguishing factors and uncertainties. Because we may be unaware of or may not adequately present various distinguishing factors and uncertainties, the comparisons set forth herein may not properly present such third-party data, which may differ materially from the data as presented here. Investors are encouraged to independently review third party data and should not rely on our presentation of such data as a single measure to evaluate our business. “Structure Therapeutics,” the Structure Therapeutics logo and other trademarks, trade names or service marks of the Company appearing in this presentation are the property of the Company. All other trademarks, trade names and service marks appearing in this presentation are the property of their respective owners. Solely for convenience, t he trademarks and trade names in this presentation may be referred to without the ® and symbols, but such references should not be construed as any indicator that their respective owners will not assert their righ ts thereto. 2 Forward-Looking Statements
Page 3
4 Our Mission Making medicines more accessible to all
Page 4
6 1. August 2025 Symphony Health prescriptio n data and 2025 Evaluate Pharma sales data 2. Trust for America’s Health Rep ort https://www.tfah .org/report- details/stateofobesity2019/#:~:text=Obesity%20is%20a%20growing%20epidemic,100%20million%20p eople%20%E2%80%93%20have%20ob es 3. Goldman Sachs Report https://www.goldmansachs.com/insights/articles/anti-obesity-drug-market 4. World Obesity 2024 https://www.worldobesity.org/about/about-obesity/prevalence-of-obesity >5 million in US1 >$100 billion Total Addressable Market3 (obesity or overweight with at least one weight-related comorbid condition) >100 million in US2 Overweight & Obesity Current Injectable Peptide GLP-1s <5% of addressable market Access to Obesity Treatments Remains a Worldwide Unmet Need Only oral small molecules can scale to meet the needs of the global obesity patient population >1 billion worldwide4 Obesity 3.0 billion people Overweight & Obesity
Page 5
5 2025 2026 2027 2028 2029 2030 Non-specialists Specialists Non- specialists = 75% Rx today and growing4 25–50M patients on treatment by 2030 5M patients on treatment today Overall obesity market is growing Estimated 25-50M treated patients in U.S. by 20301 Oral small molecules well- positioned to address unmet needs 25-50% of market could be orals, based on patient preferences and prescriber dynamics2 Obesity is expected to become a non-specialist driven disease PCPs/non-specialists favor orals due to ease of Rx and patient management3 As Obesity Market Grows, Oral Small Molecules Well-Positioned to Fill this Unmet Need Oral small molecules = biggest opportunity given PCP oral preference 1 Range of 2030 patient volume forecasts, including internal patient volume forecast Source: Goldman Sachs, McKinsey, UBS, J.P. Morgan, Morgan Stanley; internal estimates 2 Triangulation between internal data, analog disease areas, and 3rd party estimates; 3 Based on internal physician survey and interview data 4 Based on July 2025 TRx data for Wegovy. Non-specialists include PCPs, Nurse Practitioners, Physician Assistants, and Family Medicine physicians
Page 6
Small Molecules are Likely to Lead the Oral Obesity Market Given Pharmacologic and Economic Advantages Over Oral Peptides BENEFITS OF SMALL MOLECULES VERSUS ORAL PEPTIDES Oral Small Molecules Oral Peptides ADMINISTRATION No fasting requirements Typically requires pre-dose fasting COMBINATIONS Pharmacology allows fixed-dose combinations Lower feasibility for fixed-dose combinations SCALABILITY Simpler manufacturing supports future demand May struggle to scale supply to meet demand COGS Lower, offering price flexibility + margin benefits Higher, limiting pricing flexibility
Page 7
Our Approach and Pipeline
Page 8
GLP-1RA and Amylin Oral Small Molecules Represent Backbones in our Future Oral Small Molecule Metabolic Portfolio Backbone + GCGR GLP-1R + Amylin Backbones Combination Backbone + GIPR + GCGR Backbone + GIPR Potential for Indication Expansion Beyond Obesity including CKD, MASH, Hypertension, Heart Failure, Sleep Apnea, Type 2 Diabetes, Osteoarthritis, Addiction GLP-1R Aleniglipron: Phase 3 ready • Oral small molecule; once-daily dosing • Monotherapy backbonefor chronic maintenance with potential best-in-class efficacy and safety • Potential fixed-dose combination with other oral non-peptides Amylin ACCG-2671: IND cleared ACCG-3535: DC selected • Oral small molecule; once-daily dosing • Potential for tolerability advantages • Lean muscle mass preservation potential • Potential fixed-dose combinationwith other oral non-peptides 8 Important potential for: Greater body weight loss and enhanced tolerability Broader label expansion into additional clinical indications
Page 9
9 Program Molecule(s) Study / Focus Discovery Lead Optimization Development Candidate/ IND-enabling Phase 1 Phase 2 Phase 3 Selective GLP-1 Receptor Agonist Backbone Aleniglipron (GSBR-1290) ACCESS (+ OLE) ACCESS II Type 2 Diabetes +Obesity Maintenance Study Body Composition Amylin Receptor Agonists Backbone Amylin ACCG-2671 (DACRA) ACCG-3535 (DACRA) SARA Combinations GLP-1RA + Amylin GLP-1RA + Amylin Backbone + GIPR GLP-1RA + GIPR Amylin + GIPR Backbone + GCGR Backbone + GCGR Backbone + GIPR + GCGR 2026: A Transformational Year for Structure Therapeutics Discovery and Development of a Strong and Broad Portfolio of Obesity related Oral Assets
Page 10
Pro Forma ~$1.5B 1 Cash with Multiple Anticipated Catalysts Over the Next 12 Months Initiation of ACCESS OLE, ACCESS II Extension, Body Composition, Maintenance, Type 2 Diabetes studies Topline results from ACCESS Interim results from ACCESS II Interim results from Body Composition 44-week results from ACCESS II (Q1) End of Phase 2 Meeting with FDA (Q2) Initiation of pivotal Phase 3 study Topline Results ACCESS OLE Body Composition Type 2 Diabetes + Obesity/Overweight Maintenance study H2 2025 H1 2026 H2 2026 ACCG-2671 First-in-Human Phase 1 study initiated Selection of ACCG-3535 – Second DACRA Development Candidate ACCG-2671 Phase 1 study results ACCG-3535 Phase 1 study initiation AleniglipronAmylin 1. $799 million cash equivalents and short-term investments as of September 30, 2025 and $702 million net proceeds from December 2025 public offering
Page 11
Aleniglipron Selective GLP-1 Receptor Agonist Oral Small Molecule
Page 12
Aleniglipron Represents a Potential Solution in Obesity Care to be More Accessible, Scalable, and Combinable Aleniglipron Oral Small Molecule Oral Peptides Injectable Peptides ADMINISTRATION Designed as once-daily pill, no fasting Once-daily pill, typically requires pre-dose fasting Once weekly injection COMBINATIONS Observed pharmacology potentially allows for fixed-dose combinations Lower feasibility for fixed-dose combinations Lower feasibility for fixed-dose combinations SCALABILITY Simple manufacturing; ability to scale to meet global demand High dosage requirement; may struggle to scale supply to meet demand Historically struggled to meet demand COST OF GOODS Traditionalsmall molecule COGS; if approved, potential price flexibility Higher, limiting pricing flexibility Higher, limiting pricing flexibility Room temperature shipping and storage Room temperature Limited number of indicated maintenance doses (5 mg, 10 mg and 15 mg for tirzepatide) Refrigeration required for shipping and home-storage STORAGE / SUPPLYCHAIN DOSE FLEXIBILITY 12 Patient/PCP dose range flexibility; optimal for long-term maintenance TBD maintenancedose levels (top oral semaglutide dose 25 mg)
Page 13
Aleniglipron Obesity Data Summary Differentiated Selective Oral Small Molecule GLP-1R Receptor Agonist 13 Safety • > 500 participants treated across all studies up to 44 weeks o No events of drug induced liver injury o No off-target safety signals across all dose levels o No events of QTc prolongation Tolerability • Phase 2b ACCESS: o GI-related AEs consistent with GLP-1RA class o Overall 10.4% AE-related treatment discontinuations • Exploratory ACCESS II: o For those participantswho achieved re-randomization – No AE-related treatment discontinuations up to 240 mg dose • Open Label Extension (OLE) & Body Composition: o Clinically meaningful improvement in tolerability when starting at 2.5 mg compared to 5 mg start o No discontinuations observed to date* *Study ongoing and interim data from a pre-specified analysis. Interim data as of November25, 2025 Efficacy • Phase 2b ACCESS 36 week placebo-adjusted mean weight loss: o 8.2% at 45 mg o 9.8% at 90 mg o 11.3% at 120 mg • Exploratory ACCESS II 36 week placebo-adjusted mean weight loss: o 14.1% at 120 mg o 14.4% at 180 mg o 15.3% at 240 mg • No evidence of weight loss plateau • Proportional pharmacokinetic (PK) exposure up to 240 mg • Clinically meaningful improvements in blood pressure and HbA1c
Page 14
14 Phase 2b ACCESS Study Design Key Secondary Endpoints • % of participants who achieve ≥ 5%, ≥ 10% and ≥ 15% reduction in body weight at week 36 • Safety and tolerability profile of a monthly titration scheme Primary Endpoint • % change in body weight at week 36 compared to baseline (active vs. placebo) • Statistical analysis based on the Primary Efficacy Estimand 1 Study Details N=230 Participants with: • Body mass index (BMI) ≥ 30 kg/m 2 or • BMI ≥ 27 kg/m2 with ≥ 1 weight- related comorbidity Number of sites: 36 WeeksBaseline Titration Phase (every 4 weeks) Maintenance Phase (at target dose) Primary Endpoint Clinicaltrials.gov ID: NCT06693843 Open Label Extension (OLE)* 90 mg 45 mg 60 mg30 mg15 mg5 mg 30 mg15 mg5 mg 120 mg90 mg60 mg30 mg15 mg5 mg *OLE ongoing up to 72 weeks 75 mg60 mg Pooled Placebo 5 mg2.5 mg 120 mg 120 mg E-diary Reporting*0 20 36 44 N=45 N=65 N=64 N=56 1The primary efficacy estimand represents efficacy had all randomized participants remained on study treatment (with possible dose interruptions and/or dose modifications) for 36 weeks without initiating rescue weight management treatments or surgeries. 2 E-diary reporting may be associated with an increase in the number of reported events
Page 15
Baseline Demographics and Characteristics (Phase 2b ACCESS) Characteristics Mean (SD) or N (%) Aleniglipron 45 mg N=45 Aleniglipron 90 mg N=65 Aleniglipron 120 mg N=63 Placebo N=56 Age, years, mean 49.0 (12.7) 47.9 (12.5) 52.3 (13.9) 49.9 (15.8) Sex, female 25 (55.6) 35 (53.8) 35 (54.7) 30 (53.6) Weight, kg 115.6 (24.7) 117.9 (23.6) 113.1 (20.5) 112.3 (22.0) Body mass index, kg/m2 39.7 (6.9) 39.8 (7.5) 39.0 (6.4) 39.4 (7.0) HbA1c 5.7 (0.3) 5.7 (0.4) 5.7 (0.3) 5.5 (0.4) Systolic Blood Pressure, mmHg 127.0 (11.3) 126.4 (12.6) 125.3 (14.8) 125.3 (12.6) Diastolic Blood Pressure, mmHg 83.3 (7.9) 81.9 (8.0) 80.2 (8.8) 80.3 (7.9) Ethnicity (Hispanic or Latino) 7 (15.6) 9 (13.8) 9 (14.1) 11 (19.6) 15
Page 16
• 11.3% placebo-adjusted mean weight loss at 36 weeks with 120 mg • Dose dependent body weight reduction observed from 45 to 120 mg • No signs of weight loss plateau through 36 weeks across all dose ranges Aleniglipron Achieves Primary Efficacy Endpoint (Phase 2b ACCESS) 27.3 lbs24.3 lbs20.3 lbs -8.2% (-11.1 to -5.3) P<0.0001 -9.8% (-12.5 to -7.2) P<0.0001 -11.3% (-13.9 to -8.6) P<0.0001 LSM (95% CI) 45 mg 90 mg 120 mg Placebo Least-Squares Mean ( LSM) Change (%) Body Weight Placebo-adjusted Mean Body Weight Loss 16
Page 17
Aleniglipron Achieved Secondary Efficacy Endpoints (Phase 2b ACCESS) • 86% of participants with 120 mg dose achieve at least 5% body weight reduction • 70% of participants with 120 mg dose achieve at least 10% body weight reduction • 38% of participants with 120 mg dose achieve at least 15% body weight reduction • Clinically meaningful improvements in systolic blood pressure (-6.4 to -7.5 mmHg) and HbA1c (-0.28 to -0.37%) 17
Page 18
Prevalence of Nausea and Vomiting Events by Dose and Over Time (Phase 2b ACCESS) (N=45) Placebo (N=56) 120 mg (N=63) 90 mg (N=65) • Highest nausea occurs in the first weeks of starting 5 mg dose titration, mostly mild to moderate • No increase in prevalence as participants titrate to higher doses • Majority of treatment discontinuations due to AEs occurring in the first titration steps Treatment Discontinuations due to AEs (not limited to vomiting) Vomiting 18 Aleniglipron Nausea 45 mg
Page 19
Cumulative Tolerability Profile Consistent with GLP-1RA Class (Phase 2b ACCESS) N (%) Reporting at least one event* Aleniglipron 45 mg N=45 Aleniglipron 90 mg N=65 Aleniglipron 120 mg N=63 Placebo N=56 Starting Dose 5 mg 5 mg 5 mg Participants completed study on treatment 33 (73.3) 49 (75.4) 50 (78.1) 42 (75) Any TEAE leading to discontinuationof treatment 6 (13.3) 5 (7.7) 7 (11.1) 3 (5.4) Nausea 32 (71.1) 44 (67.7) 41 (65.1) 12 (21.4) Vomiting (overall) 18 (40.0) 29 (44.6) 20 (31.7) 3 (5.4) Mild and Moderate 15 (33.3) 27 (41.5) 19 (30.2) 3 (5.4) Severe 3 (6.7) 2 (3.1) 1 (1.6) 0 Diarrhea 19 (42.2) 26 (40.0) 14 (22.2) 13 (23.2) Constipation 18 (40.0) 20 (30.8) 19 (30.2) 8 (14.3) • Overall 10.4% treatment discontinuations due to AEs • No dose response in most commonly GI-reported AEs * E-diary reporting may be associated with an increase in the number of reported events 19
Page 20
• 36 week placebo-adjusted mean weight loss : o 8.2% at 45 mg o 9.8% at 90 mg o 11.3% at 120 mg • No signs of weight loss plateau • 4 week titration to optimize tolerability: o GI-related AEs consistent with GLP-1RA class o Overall 10.4% AE-related treatment discontinuations Summary Aleniglipron Topline Phase 2b ACCESS Results Phase 2b ACCESS Assess Efficacy Tolerability,Safety up to 120 mg at 36 weeks Core Focus 20
Page 21
QUESTION: Is there weight loss plateau? ACCESS OLE Study Design Study Details N=230 Participants with: • Body mass index (BMI) ≥ 30 kg/m2 or • BMI ≥ 27 kg/m2 with ≥ 1 weight- related comorbidity Number of sites: 36 WeeksBaseline Titration Phase (every 4 weeks) Maintenance Phase (at target dose) Primary Endpoint Clinicaltrials.gov ID: NCT06693843 90 mg 45 mg 60 mg30 mg15 mg5 mg 30 mg15 mg5 mg 120 mg 0 20 36 90 mg60 mg30 mg15 mg 44 N=45 N=65 N=64 5 mg N=56 Pooled Placebo 2.5 mg 5 mg 120 mg 120 mg Open Label Extension (OLE)* 60 mg 75 mg *OLE is ongoing up to 72 weeks N of participants reported = 143 ACCESS Open Label Extension Study Objectives • Long-term safety • Durability and maintenance of weight loss from Week 0 to 72 (full study), and Week 36 to 72 (OLE portion) 21 *Study ongoing and interim data from a pre-specified analysis. Interim data as of November25, 2025
Page 22
ANSWER: NO PLATEAU • Majority of eligible ACCESS participants enrolled in OLE • Weight loss continues to increase in all 4 arms of OLE through Week 44 • No evidence of weight loss plateau with transition to open label extension following Week 36 Phase 2b ACCESS (Week 0-36) ACCESS OLE* (Week 36-44) QUESTION: Is there a weight loss plateau? ACCESS OLE: Additional Body Weight Reduction Beyond 36 Weeks % Body Weight Reduction *Study ongoing and interim data as of December 2025 -2 -2.5-1-0.50 start 60 mg, current 75 mg (n=27) start 120 mg, current 120 mg (n=40) start 120 mg, current 120 mg (n=40) -3 -3.5 -3.0% start 2.5mg, current 5 mg (n=36) 22 -1.3% -1.2% -1.1% -1.5 Least-Squ ares Mean (LSM) Change (%) Bod y Weight
Page 23
22 240 mg 180 mg QUESTION: Can we dose higher than 120 mg? Exploratory ACCESS II Study Design Weeks 20 24 28 32 360 Baseline 180 mg 120 mg90 mg60 mg30 mg15 mg5 mg Study details N=85 Participants with: • Body mass index (BMI) ≥ 30 kg/m2 or • BMI ≥ 27 kg/m2 with ≥ 1 weight-related comorbidity Number of sites: 10 Clinicaltrials.gov ID: NCT06703021; 120 mg 8-Week Extension 44 Efficacy endpoint Main Study Group N=61 180 mg120 mg90 mg60 mg Sentinel Group N=12 IDMCTitration Phase 180 mg and 240 mg Dose Phase *Study still on going Pooled Placebo Conducted in Phase 1 unit 5 mg 15 mg 30 mg N=12 First Randomization Study Ongoing Re-Randomization Exploratory ACCESS II Study • Evaluate higher 180 mg and 240 mg dosing • Safety and tolerability
Page 24
Characteristics Mean (SD) or N (%) Aleniglipron Overall N=61 Placebo N=12 Age, years 49.8 (14.5) 51.8 (12.9) Sex, female 38 (62.3) 8 (66.7) Weight, kg 116.2 (31.9) 104.3 (12.38) Body mass index, kg/m2 39.9 (8.4) 36.8 (5.1) HbA1c, % 5.6 (0.35) 5.4 (0.36) Systolic Blood Pressure, mmHg 122.2 (12.2) 122.6 (11.4) Diastolic Blood Pressure, mmHg 78.7 (7.0) 82.3 (9.2) Ethnicity (Hispanic or Latino) 15 (24.6) 3 (25.0) 24 Baseline Demographics and Characteristics (Exploratory ACCESS II)
Page 25
Aleniglipron Achieved Greater Weight Loss with Higher Doses (Exploratory ACCESS II) Re-Randomization 25 Titration Phase 180 mg and 240 mg Dose Phase Least-Squares Mean (LSM) Change (%) Body Weight
Page 26
Aleniglipron Achieves Greater Weight Loss with Higher Doses (Exploratory ACCESS II – Focusing on Post Re-randomization) -14.1% (-19.0 to -9.3) P<0.0001 180 mg and 240 mg Dose Phase -14.4% (-19.1 to -9.6) P<0.0001 -15.3% (-20.1 to -10.4) P<0.0001 LSM (95% CI) 120 mg 180 mg 240 mg Placebo • Participants are on 180 mg for 8 weeks and 240 mg for 4 weeks • No evidence of weight loss plateau • Proportional exposure PK dosing up to 240 mg 26 Least-Squares Mean (LSM) Change (%) Body Weight 32.6 lbs 34.4 lbs 35.5 lbs Placebo-adjusted Mean Body Weight Loss
Page 27
Prevalence of Nausea by Dose Over Time (Exploratory ACCESS II) Post Re-Randomization • Minimal number of participants with GI-events • 2 participants with intermittent events of nausea between weeks 33-36 Severity Mild Moderate Severe Percentage of Participants(%) Post-re-randomization Nausea Placebo (N=10)Post-re-randomization Nausea Aleniglipron 240mg (N=9) Post-re-randomization Nausea Aleniglipron 180mg (N=9)Post-re-randomization Nausea Aleniglipron 120mg (N=8) 36 27 Time fromFirst Dose (Weeks) 30 33 3627 30 33 10 0 20 30 40 0 50 20 10 30 40 50 N=2 Titration Phase (Up to 120 mg) 180 mg and 240 mg Dose Phase Pre-re-randomization Nausea Pooled Aleniglipron (N=61) Percentage of participants (%) Treatment Discontinuationsdue to AEs (not limited to nausea) 120 mg phase Re-Randomization 27
Page 28
Cumulative Tolerability Results Consistent with GLP-1RA Class (Exploratory ACCESS II) Titration Phase (Up to 120 mg) 180 mg and 240mg Dosing Phase (Re-randomized Study Ongoing) N (%) Reporting at least one event* Aleniglipron Up to 120 mg N=61 Placebo N=12 Aleniglipron 120 mg to 240 mg N=26 Placebo N=10 Starting Dose 5 mg 120/180 mg Any TEAE leading to Treatment Discontinuation 17 (27.9) 0 0 0 Non-AE related Treatment Discontinuation 11 (18) 0 0 0 Non Re-randomized Participants in the Study 6 (9.8) 1 (8.3) 0 0 Nausea 42 (68.9) 0 3 (11.5) 0 Vomiting (Overall) Mild and Moderate Severe 27 (44.3) 26 (42.6) 1 (1.6) 1 (8.3) 1 (8.3) 0 3 (11.5) 3 (11.5) 0 0 0 0 Diarrhea 22 (36.1) 1 (8.3) 0 0 Constipation 13 (21.3) 2 (16.7) 0 0 No discontinuations at 120, 180, or 240 mg dose post re-randomization at 36 weeks; study ongoing to 44 weeks 29 * E-diary reporting may be associated with an increase in the number of reported events
Page 29
QUESTION: Will lower 2.5 mg starting dose further improve tolerability? OLE and Body Composition Study Design Body Composition Study Objectives • Evaluate tolerability with 2.5 mg starting dose • Assess body fat loss over 40 weeks to inform body composition endpoints in Phase 3 Study Details N=71 Participants with: • Body mass index (BMI) ≥ 30 kg/m2 Number of sites: 11 Clinicaltrials.gov ID: NCT06693843 Study Ongoing *Study ongoing and interim data from a pre-specified analysis. Interim data as of November 25, 2025 Study Ongoing 30
Page 30
Baseline Demographics and Characteristics (Body Composition Study) 31 Characteristics Mean (SD) or N (%) Aleniglipron N=59 Placebo N=12 Age, years, mean 54.5 (11.4) 48.8 (16.4) Sex, female 38 (64.4) 8 (66.7) Weight, kg 108.0 (20.2) 111.2 (20.8) Body mass index, kg/m2 38.1 (6.2) 39.6 (6.8) HbA1c (%) 5.6 (0.3) 5.6 (0.3) Ethnicity (Hispanic or Latino) 4 (6.8) 4 (33.3) *Study ongoing and interim data from a pre-specified analysis. Interim data as of November 25, 2025
Page 31
Severit Mild Moderate Severe Prevalence of Nausea and Vomiting by Dose Over Time (Body Composition Study) Nausea Aleniglipron (N=59) Nausea Placebo (N=12) 9 12 15 18 21 24 27 30 33 36 0 3 6 Time from First Dose (Weeks) 9 12 15 18 21 24 27 30 33 360 3 6 0 10 20 30 50 40 Percentage of Participants(%) Severit Mild Moderate Severe Vomiting Placebo (N=12)Vomiting Aleniglipron (N=59) 9 12 15 18 21 24 27 30 33 36 0 3 6 Time from First Dose (Weeks) 9 12 15 18 21 24 27 30 33 360 3 6 20 10 0 30 50 40 Percentage of Participants(%) NauseaVomiting Study ongoing Study ongoing Study ongoing Study ongoing Nausea and Vomiting *Study ongoing and interim data from a pre-specified analysis. Interim data as of November 25, 2025 32 • Low percentage No treatment discontinuations due to AEs
Page 32
Cumulative Aleniglipron Tolerability Results with 2.5 mg Starting Dose (Body Composition Study) N (%) Reporting at least one event Aleniglipron N=59 Placebo N=12 Starting Dose 2.5 mg Any TEAE 42 (71.2) 9 (75.0) Any TEAE leading to discontinuation of treatment 0 0 Nausea 21 (35.6) 2 (16.7) Vomiting 5 (8.5) 0 Diarrhea 11 (18.6) 3 (25.0) Constipation 15 (25.4) 3 (25.0) Study Ongoing • No treatment discontinuations due to AEs after a median treatment of ~10 weeks* 33 *Study ongoing and interim data from a pre-specified analysis. Interim data as of November 25, 2025
Page 33
22 21.1 5.7 15.3 6.56.9 11.3 0 1.7 4.3 0 5 10 15 20 25 30 35 40 50 Nausea Vomiting QUESTION: Will lower 2.5 mg starting dose further improve tolerability? Tolerability with 5 mg vs 2.5 mg Starting Dose Percentage of participants Open Label Extension 2.5 mg to 5 mg ACCESS and ACCESS II start at 5 mg Body Composition (BC) 2.5 mg to 5 mg ACCESS 5 mg Week 1 – 4 N=173 ACCESS-II 5 mg Week 1 – 4 N=71 OLE 2.5 Week 1 – 4 0 0 OLE 5 mg Week 5 – 8 BC 2.5 mg Week 1 – 4 BC 5 mg Week 5 – 8 N=36 N=59 Study ongoing and interim data from a pre-specified analysis. Interim data as of November 25, 2025 Answer: • Tolerability improved with lo4w5 er 2.5 mg starting dose 34 • No treatment discontinuations due to AEs after a median treatment of ~10 weeks* Rationale: • Peak of GI-related events in ACCESS program occurred at the 5 mg starting dose • Majority of treatment discontinuations in ACCESS program occurred during the first 12 weeks
Page 34
35 Aleniglipron Demonstrated Favorable Off-Target Safety Results N (%) Phase 2b ACCESS (up to 120 mg) ACCESS OLE1 Exploratory ACCESS II (up to 240 mg) Body Composition2 45 mg N=45 90 mg N=65 120 mg N=63 Placebo N=56 N=143 N=61 Placebo N=10 N=59 Placebo N=12 ALT ≥ 3x ULN 1 (2.3) 3 (4.8) 2 (3.2) 1 (1.8) 2 (1.4) 0 0 0 0 ALT ≥ 5x ULN 0 1 (1.6) 0 0 1 (0.7) 0 0 0 0 ALT ≥ 10x ULN 0 0 0 0 0 0 0 0 0 AST ≥ 3x ULN 0 0 0 1 (1.8) 0 1 (1.7) 0 0 0 AST ≥ 5x ULN 0 0 0 0 0 1 (1.7) 0 0 0 AST ≥ 10x ULN 0 0 0 0 0 0 0 0 0 ALT or AST ≥ 3 x ULN Total Bilirubin ≥ 2 x ULN 0 0 0 0 0 0 0 0 0 • No cases of drug-induced liver injury • No cases of ALT or AST ≥ 10x upper limit of normal (ULN) • All cases of elevated ALT and AST resolved without treatment discontinuation 1 Interim data as of November 26, 2025 2 Interim data as of November 25, 2025
Page 35
Compelling Data Package to Advance into Phase 3* Manufacturing Phase 3 API manufacturing completed Phase 3 Drug Product manufacturing underway Next Step: Conduct End of Phase 2 meeting with FDA to confirm registrational Phase 3 program Phase 2b ACCESS Assess Efficacy Tolerability,Safety up to 120 mg at 36 weeks Core Focus Key Questions Answers Is there weight loss plateau beyond 36 weeks? Can we dose greater than 120 mg? Will lower 2.5 mg starting dose further improve tolerability? Phase 3 Ready Chronic Weight Management * Subject to FDA approval 2.5 mg starting dose has demonstrated improved tolerability No weight loss plateau beyond 36 weeks Additional weight loss confirmed with multiple doses up to 240 mg 40
Page 36
42 Aleniglipron is Differentiated and We Believe is Well Positioned to Capture a Significant Proportion of the Growing Obesity Market Non-specialists Specialists Non- specialists = 75% Rx today and growing3 Only > 5M patients on incretin treatment today in US2 2025 2026 2027 2028 2029 2030 • PCPs/non-specialists indicate higher preference for orals due to convenience & potential for broader access and coverage4 • Orals represent an exciting new option for long-term maintenance; more optionality for patients could facilitate improved persistence • Oral small molecules well-positioned to address unmet needs; 25-50% of market could be orals5 1. World Obesity Atlas 2024https://s3-eu-west-1.amazonaws.com/wof-files/WOF_Obesity_Atlas_2024.pdf 2. August 2025Symphony Health prescription data and 2025 Evaluate Pharma sales data 3 Kumar et al., ISPOR (2025). https://www.ispor.org/docs/default-source/cti-meeting-21021-documents/6fe2eb97-d003-4dc0-b6d0-812e13795055.pdf?sfvrsn=45a94bc8_0.Based on July 2025 TRx data for Wegovy. Non-specialists include PCPs, Nurse Practitioners,Physician Assistants, and Family Medicine physicians 4 Based on internal physiciansurveyand interview data 5.Triangulationbetween internal data, analogdiseaseareas, and 3rd party estimates; • 15.3% placebo-adjusted mean weight loss at 36 weeks with 240 mg • Proportional exposure up to 240 mg • No evidence of weight loss plateau • 2.5 mg start further improves tolerability • Scaleable to meet global demand Only oral small molecules can scale and meet the needs of the global obesity patient population, estimated to be 1.5 billion by 20301 GLP-1R Aleniglipron
Page 37
ACCG-2671 Lead Amylin Receptor Agonist 38
Page 38
39 ACCG-2671: Oral Small Molecule Amylin Receptor Agonist Development Candidate Criteria Target Product Profile Competitive Efficacy Comparable preclinical efficacy to cagrilintide – a dual amylin calcitonin receptor agonist (DACRA) peptide Safety Suitable for chronic disease treatment Pharmacokinetics Predicted once daily oral dosing Scalability Manufacturable and scalable at low COGS Combinability Combinable with small molecule GLP-1RA and other incretins
Page 39
40 Preclinical Results Support Development Candidate Selection Oral Small Molecule ACCG-2671 Injectable Peptide Cagrilintide In vitro affinity Ki hAMY3R <5 nM 3.5 nM Ki hCTR <5 nM 6.8 nM In vivo efficacy Bodyweight loss (DIO rats) 14.8% @15 mpk p.o. QD 11.4% @7.5nmol/kg s.c. QD Preclinical Safety In vivo Tolerability up to 300mpk (rat dose range finding) N/A In vitro hERG (>100x) GSH Negative N/A Human Dose Dose & frequency Predicted <100 mg / QD 2.4 mg s.c. / QW Note: The in-house data included here are based on preclinical studies conducted by the Company except for human dose. In vivo efficacy data are based on separate preclinical DIO studies of cagrilintide and ACCG-2671 GSH: Glutathione trapping liver microsomes assay; hERG: human ether-a-go-go-related gene potassium channel ACCG-2671 Profile • Dual Amylin and Calcitonin Receptor Agonist (DACRA) • Nanomolar in vitro binding affinity to amylin and calcitonin receptors • Sub-nanomolar in vitro functional activity on amylin and calcitonin receptors • In vivo efficacy comparable to cagrilintide DACRA in Diet-Induced Obesity (DIO) models • Robust efficacy in combination treatment with semaglutide in DIO models • Preclinical safety profile supports development candidate selection • Preclinical PK supports once-daily oral dosing in human
Page 40
Arm 2 – Crossover (fed) ACCG-2671: Ongoing Phase 1 SAD Study- Trial Design 41 Evaluate the safety, tolerability, pharmacokinetics (PK), and food-effect of single ascending doses of ACCG-2671 in healthy adult participants Part 1 (n=40) Single Ascending Dose (SAD) to measure safety, tolerability and pharmacokinetics (PK) 3:1 randomization (active:placebo) 5 dose cohorts Arm 1 (fed) Arm 2 (fasted) Arm 1 – Crossover (fasted) 1 mg 2 mg 5 mg 10 mg 20 mg Study Details N=52 total Two parts Healthy adults 25-65 years old BMI ≥18 kg/m2 and ≤30 kg/m2 Part 2 (n=12) Effect of food intake on the PK, safety, and tolerability of a single dose of ACCG-2671 Open-label, 2-treatment arm, 2-period crossover Single low-dose
Page 41
2026 Catalyst-driven year for Structure Therapeutics 42
Page 42
43 Program Molecule(s) Study / Focus Discovery Lead Optimization Development Candidate/ IND-enabling Phase 1 Phase 2 Phase 3 Selective GLP-1 Receptor Agonist Backbone Aleniglipron (GSBR-1290) ACCESS (+ OLE) ACCESS II Type 2 Diabetes +Obesity Maintenance Study Body Composition Amylin Receptor Agonists Backbone Amylin ACCG-2671 (DACRA) ACCG-3535 (DACRA) SARA Combinations GLP-1RA + Amylin GLP-1RA + Amylin Backbone + GIPR GLP-1RA + GIPR Amylin + GIPR Backbone + GCGR Backbone + GCGR Backbone + GIPR + GCGR 2026: A Transformational Year for Structure Therapeutics Discovery and Development of a Strong and Broad Portfolio of Obesity related Oral Assets
Page 43
Pro Forma ~$1.5B 1 Cash with Multiple Anticipated Catalysts Over the Next 12 Months Initiation of ACCESS OLE, ACCESS II Extension, Body Composition, Maintenance, Type 2 Diabetes studies Topline results from ACCESS Interim results from ACCESS II Interim results from Body Composition 44-week results from ACCESS II (Q1) End of Phase 2 Meeting with FDA (Q2) Initiation of pivotal Phase 3 study Topline Results ACCESS OLE Body Composition Type 2 Diabetes + Obesity/Overweight Maintenance study H2 2025 H1 2026 H2 2026 ACCG-2671 First-in-Human Phase 1 study initiated Selection of ACCG-3535 as Second DACRA Development Candidate ACCG-2671 Phase 1 study results ACCG-3535 Phase 1 study initiation AleniglipronAmylin 1. $799 million cash equivalents and short-term investments as of September 30, 2025 and $702 million net proceeds from December 2025 public offering
Page 44
46 Our Mission Making medicines more accessible to all